Imeglimin is the first in a new tetrahydrotriazine-containing class of oral antidiabetic agents. It has been shown to act on the liver, muscle, and pancreatic β-cells to uniquely target the key defects of type 2 diabetes.

775351-65-0

C6H13N5

155.2

Imeglimin

DMSO:Soluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years